Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include Medicine, Virology, Antibody, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Vaccination, and Neutralization.
Development of a Liposome-Based Serological Assay for SARS-CoV-2 Variants with Special Emphasis on Coupling Chemistries Required to Maintain Protein Antigenicity
Development of a Novel Homogeneous Liposome-Based One-Step Assay for SARS-CoV-2 Antibody Detection in Human Serum Based on Fluorescent Liposomes and Complement Activity
Digitally Immune-Optimised Next-Generation Influenza H5Nx Vaccination Provides Protection with Broad Cross-Clade Neutralisation Against Global Threats
Digitally Immune-Optimised Next-Generation Influenza Vaccine Provides Cross-Clade Protection Against Emerging H5Nx Viruses
Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccine
Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants
Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection
Impedance‐based monitoring of titration and neutralization assays with VSV‐G and SARS‐CoV‐2‐spike pseudoviruses
A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses
Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera
Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Evolution of protective SARS-CoV-2-specific B- and T-cell responses upon vaccination and Omicron breakthrough infection
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants
Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County—Results from a Population-Based Longitudinal Study in Germany
Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020
Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19
Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests—A Population-Based Evaluation
Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020
Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross Sectional-Population of German Children
Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds